Gsa Capital Partners LLP Acadia Pharmaceuticals Inc Transaction History

Gsa Capital Partners LLP

$1.43 Billion
Q2 2025

A detailed history of Gsa Capital Partners LLP transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Gsa Capital Partners LLP holds 24,474 shares of ACAD stock, worth $622,863. This represents 0.04% of its overall portfolio holdings.

Number of Shares

24,474

Previous 79,293 69.13%

Holding current value

$622,863

Previous $1.32 Million 59.91%

% of portfolio

0.04%

Previous 0.12%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Jul 22, 2025	SELL	$14.1 - $22.95 $772,947 - $1.26 Million	-54,819 Reduced 69.13%	24,474 $528,000
Q1 2025 May 08, 2025	BUY	$16.61 - $20.29 $95,773 - $116,992	5,766 Added 7.84%	79,293 $1.32 Million
Q4 2024 Feb 07, 2025	BUY	$14.29 - $18.76 $91,898 - $120,645	6,431 Added 9.58%	73,527 $1.35 Million
Q3 2024 Nov 05, 2024	SELL	$15.14 - $19.14 $1.72 Million - $2.17 Million	-113,604 Reduced 62.87%	67,096 $1.03 Million
Q2 2024 Aug 15, 2024	BUY	$14.62 - $18.42 $1.01 Million - $1.28 Million	69,306 Added 62.22%	180,700 $2.94 Million
Q1 2024 May 03, 2024	BUY	$17.79 - $30.86 $1.74 Million - $3.02 Million	97,987 Added 730.86%	111,394 $2.06 Million
Q4 2023 Feb 16, 2024	SELL	$20.78 - $31.77 $1.38 Million - $2.11 Million	-66,442 Reduced 83.21%	13,407 $419,000
Q3 2023 Nov 15, 2023	BUY	$20.84 - $33.47 $1.19 Million - $1.91 Million	57,119 Added 251.29%	79,849 $1.66 Million
Q2 2023 Aug 14, 2023	BUY	$17.8 - $25.65 $404,594 - $583,024	22,730 New	22,730 $544,000
Q2 2022 Aug 09, 2022	BUY	$13.01 - $27.22 $396,115 - $828,767	30,447 New	30,447 $429,000
Q4 2021 Feb 14, 2022	SELL	$16.79 - $27.09 $1.15 Million - $1.85 Million	-68,330 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$15.78 - $24.77 $1.08 Million - $1.69 Million	68,330 New	68,330 $1.14 Million
Q1 2020 May 12, 2020	SELL	$31.65 - $46.87 $300,231 - $444,608	-9,486 Closed	0 $0
Q4 2019 Feb 12, 2020	SELL	$36.21 - $51.4 $41,713 - $59,212	-1,152 Reduced 10.83%	9,486 $406,000
Q3 2019 Nov 12, 2019	BUY	$22.22 - $44.01 $236,376 - $468,178	10,638 New	10,638 $383,000
Q4 2018 Feb 12, 2019	SELL	$14.32 - $22.92 $167,787 - $268,553	-11,717 Closed	0 $0
Q3 2018 Nov 13, 2018	BUY	$13.03 - $21.81 $152,672 - $255,547	11,717 New	11,717 $243,000

Others Institutions Holding ACAD

# of Institutions

345

Shares Held

164M

Call Options Held

811K

Put Options Held

334K

View Full List

About ACADIA PHARMACEUTICALS INC

Ticker ACAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 161,843,008
Market Cap $4.12B
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...

More about ACAD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.

Account

Gsa Capital Partners LLP Acadia Pharmaceuticals Inc Transaction History